James M. Inhofe bought SPDR S&P Biotech ETF (XBI)
James M. Inhofe (R-OK), a U.S. Senator, has disclosed 2 trades in SPDR S&P Biotech ETF (XBI) since 2018, 1 purchase and 1 sale, worth an estimated $65K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: James M. Inhofe bought $15,001 - $50,000 of SPDR S&P Biotech ETF (XBI) on December 31, 2018. Since that trade, XBI is up +107.76% against the S&P 500 up +225.44%, an outperformance of -117.68%.
Across these filings, James M. Inhofe has been a balanced trader of XBI (a buy-to-sell ratio of 1.00). The most recent disclosed XBI transaction shown was dated September 30, 2019. Each row in the table below links to that trade and its post-trade performance versus the market.
Data updated
James M. Inhofe's XBI trades vs the price
XBI is up +107.76% since James M. Inhofe bought on December 31, 2018, versus +225.44% for the S&P 500.
Performance since this trade
All James M. Inhofe XBI trades
James M. Inhofe & XBI trading FAQ
Is it legal for James M. Inhofe to trade SPDR S&P Biotech ETF (XBI) stock?
Yes. Members of Congress are allowed to trade individual stocks, including SPDR S&P Biotech ETF (XBI), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did James M. Inhofe buy XBI?
James M. Inhofe disclosed a purchase of $15,001 - $50,000 of SPDR S&P Biotech ETF (XBI) on December 31, 2018, according to public STOCK Act filings.
How has XBI performed since James M. Inhofe's trade?
Since James M. Inhofe bought XBI on December 31, 2018, the stock is up +107.76%, versus +225.44% for the S&P 500 over the same period, an outperformance of -117.68%.
How many times has James M. Inhofe traded XBI?
James M. Inhofe has disclosed 2 XBI trades since 2018 (1 purchase and 1 sale). Every disclosed trade is listed on this page.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional XBI trades?
Quantellect tracks every disclosed congressional trade in SPDR S&P Biotech ETF (XBI) on the SPDR S&P Biotech ETF congressional trading page, which aggregates filings across all members of Congress.
James M. Inhofe's XBI tradesAll congressional filings for SPDR S&P Biotech ETFJames M. Inhofe's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.